Creative Medical Technology Holdings (CELZ) EBITDA Margin (2017 - 2025)
Creative Medical Technology Holdings (CELZ) posted quarterly EBITDA Margin of 64859.4% for Q4 2025, down 200160.0% year-over-year from N/an in Q4 2024, and down 17.18% quarter-over-quarter from 55349.27% in Q1 2025.
Creative Medical Technology Holdings (CELZ) EBITDA Margin (2017 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported EBITDA Margin for 9 consecutive years, with 64859.4% the latest figure, recorded in Q4 2025.
- In Q4 2025, EBITDA Margin fell 200160.0% year-over-year to 64859.4%; the TTM figure through Mar 2026 stood at 198049.63% (down 15318398.0% YoY), while the FY2025 annual figure was 102380.23%, down 5016332.0% from the prior year.
- EBITDA Margin slipped to 64859.4% in Q4 2025 per CELZ's latest filing, from 55349.27% in the prior quarter.
- Across five years, EBITDA Margin topped out at 1855.31% in Q3 2022 and bottomed at 64859.4% in Q4 2025.
- Historically, EBITDA Margin has averaged 28928.09% across 5 years, with a median of 23018.04% in 2024.
- On a YoY basis, EBITDA Margin climbed as much as 647905 bps in 2022 and fell as far as 3157871 bps in 2022.
- Creative Medical Technology Holdings' EBITDA Margin stood at 2173.64% in 2021, then tumbled by 1453 bps to 33752.35% in 2022, then plunged by 75 bps to 59061.3% in 2023, then slipped by 6 bps to 62857.8% in 2024, then decreased by 3 bps to 64859.4% in 2025.
- Business Quant data shows CELZ's EBITDA Margin at 64859.4% in Q4 2025, 55349.27% in Q1 2025, and 62857.8% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -64,859.40% |
| Mar 31, 2025 | -55,349.27% |
| Dec 31, 2024 | -62,857.80% |
| Jun 30, 2024 | -20,316.33% |
| Dec 31, 2023 | -59,061.30% |
| Sep 30, 2023 | -25,719.75% |
| Dec 31, 2022 | -33,752.35% |
| Sep 30, 2022 | -1,855.31% |
| Mar 31, 2022 | -7,699.13% |
| Dec 31, 2021 | -2,173.64% |
| Sep 30, 2021 | -8,334.36% |
| Jun 30, 2021 | -5,158.42% |
| Dec 31, 2020 | -1,846.08% |
| Sep 30, 2020 | -314.90% |
| Jun 30, 2020 | -767.97% |
| Mar 31, 2020 | -795.81% |
| Dec 31, 2019 | 7,513.39% |
| Sep 30, 2019 | -475.52% |
| Jun 30, 2019 | -447.17% |
| Mar 31, 2019 | -493.50% |